Page 144 - 2021_10-Haematologica-web

P. Strati et al.
onset cytopenia. Cancer-Am Cancer Soc.
2013;119(21):3805-3811.
16. Tam CS, O'Brien S, Wierda W, et al. Long-
term results of the fludarabine, cyclophos- phamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia. Blood. 2008;112(4):975-980.
17. Brudno JN, Somerville RP, Shi V, et al. Allogeneic T cells that express an anti-CD19 chimeric antigen receptor induce remissions of B-cell malignancies that progress after allogeneic hematopoietic stem-cell trans- plantation without causing graft-versus-host disease. J Clin Oncol. 2016;34(10):1112- 1121.
18. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraft- ment of autologous peripheral-blood stem
cells. J Clin Oncol. 1995;13(10):2547-2555. 19. Hill JA, Li D, Hay KA, et al. Infectious com- plications of CD19-targeted chimeric anti- gen receptor-modified T-cell immunothera-
py. Blood. 2018;131(1):121-130.
20. Park JH, Romero FA, Taur Y, et al. Cytokine
release syndrome grade as a predictive marker for infections in patients with relapsed or refractory B-cell acute lym- phoblastic leukemia treated with chimeric antigen receptor T cells. Clin Infect Dis. 2018;67(4):533-540.
21. Jung AC, Paauw DS. Diagnosing HIV-relat- ed disease: using the CD4 count as a guide. J Gen Intern Med. 1998;13(2):131-136.
22. Schuster SJ, Svoboda J, Chong EA, et al. Chimeric antigen receptor T cells in refracto- ry B-cell lymphomas. N Engl J Med.
2017;377(26):2545-2554.
23. Brudno JN, Kochenderfer JN. Toxicities of
chimeric antigen receptor T cells: recogni- tion and management. Blood. 2016;127(26) :3321-3330.
24. Hattori N, Saito B, Sasaki Y, et al. Status of natural killer cell recovery in day 21 bone marrow after allogeneic hematopoietic stem cell transplantation predicts clinical out- come. Biol Blood Marrow Transplant. 2018;24(9):1841-1847.
25. Chang YJ, Zhao XY, Huang XJ. Effects of the NK cell recovery on outcomes of unmanipu- lated haploidentical blood and marrow transplantation for patients with hematolog- ic malignancies. Biol Blood Marrow Transplant. 2008;14(3):323-334.
2672
haematologica | 2021; 106(10)